Nursing and Health Professions
Combination Therapy
44%
Ribavirin
44%
Patient
44%
Alpha2a Interferon
44%
Peginterferon Alpha
44%
Sustained Virologic Response
33%
Neutrophil Count
33%
Treatment Duration
22%
Chronic Hepatitis C
22%
Hemoglobin Blood Level
22%
Platelet Count
22%
Drug
22%
Parameters
22%
Relapse
22%
Body Weight Loss
22%
Pharmacodynamics
22%
Weight
22%
Neutropenia
11%
Body Weight
11%
Deterioration
11%
Alanine Aminotransferase Level
11%
Post Hoc Analysis
11%
Virus RNA
11%
Ethnic Groups
11%
Hispanic
11%
Male
11%
Cytopenia
11%
Immunology and Microbiology
Peginterferon Alpha
44%
Ribavirin
44%
Alpha2a Interferon
44%
Weight
44%
Hepatitis C Virus
33%
Neutrophil Count
33%
Platelet Count
22%
Pharmacodynamics
22%
Hepatitis C Virus Genotype 1
22%
Drug Exposure
22%
Hemoglobin Blood Level
22%
Body Weight
11%
Neutrophil Granulocyte
11%
Ethnicity
11%
Host
11%
Hepatitis C
11%
Platelet
11%
Alanine Aminotransferase Level
11%
Association
11%
Race
11%
Experience
11%
Viral Disease
11%
Physics
Responses
100%
Viruses
55%
Therapy
55%
Interferon
44%
Ribavirin
44%
Platelets
33%
Hemoglobin
22%
Drugs
22%
Independent Variables
22%
Adjusting
22%
RNA
11%
Differences
11%
Significance
11%
Biochemistry, Genetics and Molecular Biology
Weight
44%
Hepatitis C Virus
33%
Neutrophil Count
33%
Pharmacodynamics
22%
Platelet Count
22%
Hemoglobin Blood Level
22%
Drug Exposure
22%
Hepatitis C Virus Genotype 1
22%
Relapse
22%
RNA Virus
11%
Body Weight
11%
Platelet
11%
Ethnicity
11%
Host
11%
Alanine Aminotransferase Level
11%
Association
11%
Race
11%
Experience
11%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha2a Interferon
44%
Ribavirin
44%
Peginterferon Alpha
44%
Hepatitis C Virus
22%
Drug
22%
Chronic Hepatitis C
22%
Hepatitis C Virus Genotype 1
22%
Relapse
22%
Neutropenia
11%
Deterioration
11%
Cytopenia
11%
Host
11%